Pennant

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, with revenue of $298.0M exceeding the $288.7M estimate and Adjusted EPS of $0.36 surpassing the $0.33 mean. Growth was primarily driven by the Home Health and Hospice segment, where revenue rose 43.2% YoY, supported by a 62.3% surge in total home health admissions. Management raised FY26 guidance, now projecting revenue of $1.17B–$1.19B and Adjusted EPS of $1.34–$1.41, both trending above previous expectations.